Magazine Article | July 1, 2020

OTC Drug Monograph Reform In The CARES Act

Source: Life Science Leader

By Kalah Auchincloss

In March, Congress included in the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) long-awaited reforms to the FDA’s regulation of OTC drugs. Consumers, industry, and others had argued for years that the FDA’s oversight of OTC drugs was antiquated and in need of an overhaul.

Provisions like those included in the CARES Act were discussed (but ultimately not included) as part of FDA-related legislation enacted in 2016 and had subsequently passed both the House and Senate in various forms over the last two years. The changes included in the CARES Act are intended to address challenges with the old system, allowing more nimble OTC oversight and potentially ushering in a new era of OTC safety and innovation.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: